Two-week intervals during omalizumab treatment may provide better symptom control in selected patients with chronic urticaria


Turk M., Kocaturk E., Cure K., YILMAZ İ.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, vol.6, no.4, pp.1389-1390, 2018 (SCI-Expanded, Scopus)